We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

There are several risk factors for osteoporosis and osteoporotic fractures including age, sex, fragility fracture after the age of 40, use of glucocorticoid drugs, medications, medical conditions that inhibit absorption […]

Important Changes to the Availability and Conditions of Use for Drugs Containing Calcitonin Calcitonin nasal spray for the treatment of osteoporosis is no longer available in Canada because of new […]

For those living with osteoporosis, there are a variety of treatment options available. The primary goal of treatment is to prevent or slow bone loss and reduce the risk of […]

SERMS Selective Estrogen Receptor Modulators Raloxifene (Evista®) is from a family of drugs called SERMs (Selective Estrogen Receptor Modulators). How Does Raloxifene Work? During their reproductive years, women produce significant […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

Medications that can Cause Bone Loss, Falls and/or Fractures A variety of medications can increase bone loss and/or fall risk: Synthetic Glucocorticoids (e.g. Prednisone) Glucocorticoids are produced naturally by the […]

New survey reveals Canadians are largely unaware about osteoporosis and the serious consequences it can have on their health TORONTO, ON (February 2, 2016) – Snow and ice can make walking […]